NCT04208386View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Hepatic Impairment
Interventions
DRUG

JNJ-73763989

JNJ-73763989 will be administered SC under fasted condition.

Trial Locations (1)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT04208386 - A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 | Biotech Hunter | Biotech Hunter